Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to T Cell-Mediated Inflammatory and Immune Diseases
Retrieved on:
Wednesday, November 1, 2023
T helper 17 cell, Psoriasis, Medical research, Pulmonary fibrosis, Publication, Scleroderma, Preprint, Immunodeficiency, TGF, RNA, Cytokine, Fibrosis, GVHD, Research, Inflammation, INSERM, ITK, Induction, MMP2, Hôpital Cochin, Systemic, Clinical trial, Asthma, Atopic dermatitis, Cancer, IL-5, Memorial Sloan Kettering Cancer Center, Lymphoma, Chronic obstructive pulmonary disease, COPD, Enteropathy-associated T-cell lymphoma, Lupus, Extractive metallurgy, Vaccine, Rheumatology, Corvus, T helper cell
BURLINGAME, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the publication of preclinical data that demonstrated the potential of ITK inhibition as a novel approach to treat T cell-mediated inflammatory and immune diseases. Corvus’ ITK inhibitors include soquelitinib (formerly known as CPI-818), which was used in the preclinical studies and is currently in clinical trials for oncology indications, and several next-generation molecules that are being optimized for use in a variety of inflammatory and immune disease indications.
Key Points:
- “Our research on soquelitinib and selective ITK inhibition is uncovering valuable new information about immune function and the role of ITK in different diseases,” said James Rosenbaum, M.D., senior vice president of research at Corvus.
- “The activity of soquelitinib in various inflammatory and immune disease models highlights the essential role of ITK in multiple T cell functions.
- The publication is now available online as a preprint at bioRxiv.org and on the Publications and Presentations page of the Corvus website.
- With this new publication, we further demonstrate the wide range of opportunities for ITK inhibition across specific indications with ongoing patient needs for new therapies.